Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 518Breast Neoplasms 456Lung Neoplasms 252Prostatic Neoplasms 234Colorectal Neoplasms 216Carcinoma, Non-Small-Cell Lung 185Pancreatic Neoplasms 154Carcinoma, Hepatocellular 136Stomach Neoplasms 134Ovarian Neoplasms 116Multiple Myeloma 98Melanoma 93Head and Neck Neoplasms 93Esophageal Neoplasms 90Disease 87Urinary Bladder Neoplasms 85Uterine Cervical Neoplasms 78Lymphoma 78Brain Neoplasms 75Liver Neoplasms 74Hematologic Neoplasms 74Endometrial Neoplasms 71Leukemia, Myeloid, Acute 66Neoplasm Metastasis 65Colonic Neoplasms 61Rectal Neoplasms 60Precursor Cell Lymphoblastic Leukemia-Lymphoma 56Sarcoma 53Leukemia 53Glioma 53

Interventions

Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Observational × Immune-Related Adverse Events × Clear all
NCT07453342 2026-03-06

Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge

Peking Union Medical College Hospital

Recruiting
500 enrolled

Immune-Related Adverse Events

Data powered by HemOnc (CC BY 4.0) Colophon âš¡